Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
JD Mitchell, JH Wokke, GD Borasio - The Cochrane Database of …, 2002 - europepmc.org
JD Mitchell, JH Wokke, GD Borasio
The Cochrane Database of Systematic Reviews, 2002•europepmc.orgBackground Trophic factors, including recombinant human insulin-like growth factor I have
been postulated as possible disease modifying therapies for amyotrophic lateral sclerosis.
Randomised clinical trials of recombinant human insulin-like growth factor I in amyotrophic
lateral sclerosis to date have yielded conflicting results. Objectives The main objective of this
review was to examine the efficacy of recombinant human insulin-like growth factor I in
amyotrophic lateral sclerosis. Occurrence of adverse events has also been reviewed.
been postulated as possible disease modifying therapies for amyotrophic lateral sclerosis.
Randomised clinical trials of recombinant human insulin-like growth factor I in amyotrophic
lateral sclerosis to date have yielded conflicting results. Objectives The main objective of this
review was to examine the efficacy of recombinant human insulin-like growth factor I in
amyotrophic lateral sclerosis. Occurrence of adverse events has also been reviewed.
Background
Trophic factors, including recombinant human insulin-like growth factor I have been postulated as possible disease modifying therapies for amyotrophic lateral sclerosis. Randomised clinical trials of recombinant human insulin-like growth factor I in amyotrophic lateral sclerosis to date have yielded conflicting results.
Objectives
The main objective of this review was to examine the efficacy of recombinant human insulin-like growth factor I in amyotrophic lateral sclerosis. Occurrence of adverse events has also been reviewed.
europepmc.org